There is a future for stem cell technology for treating CLI

Dong-il Kim, MD, PhD, FACS
Division of Vascular Surgery, Samsung Medical Center, Sungkyunkwan University, Seoul, Korea

Nothing to disclose

Clinical trials using stem cells: Global & Korea

<table>
<thead>
<tr>
<th></th>
<th>Global</th>
<th>Korea</th>
<th>Global</th>
<th>Korea</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cell therapy</td>
<td>260</td>
<td>46</td>
<td>945</td>
<td>24</td>
<td>1,274</td>
</tr>
<tr>
<td>Regenerative medicine</td>
<td>222</td>
<td>0</td>
<td>189</td>
<td>0</td>
<td>412</td>
</tr>
<tr>
<td>Total</td>
<td>482</td>
<td>46</td>
<td>1,134</td>
<td>24</td>
<td>1,686</td>
</tr>
</tbody>
</table>

* IIT: Investigator Initiated Trials
* SIT: Sponsor Initiated Trials

Clinical trials in the world using stem cells

* Blue: mesenchymal stem cell

Animal study (Dog): angiogram

Animal study (mouse): LASER Doppler
Angiographic findings: human

Autologous Whole Bone Marrow Stem Cell Transplantation
- Periods: From Mar. 2013 to Sep. 2017
- Limbs: 78 limbs
- Diagnosis: Buerger's disease
- Age: 44.4 ± 10.3 year

Cell counts: MNC & CD 34+

<table>
<thead>
<tr>
<th>Day</th>
<th>Preoperative day</th>
<th>Op day</th>
<th>Postoperative day</th>
<th>BM Op day</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total MNCs/ml</td>
<td>3.15 × 10⁶ ± 0.74 × 10⁶</td>
<td>3.85 × 10⁶ ± 0.87 × 10⁶</td>
<td>3.45 × 10⁶ ± 0.70 × 10⁶</td>
<td>3.14 × 10⁷ ± 3.10 × 10⁷</td>
</tr>
<tr>
<td>Mean No.</td>
<td>2.80 × 10⁵ ± 1.65 × 10⁵</td>
<td>5.67 × 10⁵ ± 3.71 × 10⁵</td>
<td>4.42 × 10⁴ ± 3.98 × 10⁴</td>
<td></td>
</tr>
<tr>
<td>CD 34+ (ml)</td>
<td>2.80 × 10⁶ ± 0.74 × 10⁶</td>
<td>5.67 × 10⁶ ± 3.71 × 10⁶</td>
<td>4.42 × 10⁵ ± 3.98 × 10⁵</td>
<td></td>
</tr>
<tr>
<td>Mean No.</td>
<td>2.80 × 10⁵ ± 1.65 × 10⁵</td>
<td>5.67 × 10⁵ ± 3.71 × 10⁵</td>
<td>4.42 × 10⁴ ± 3.98 × 10⁴</td>
<td></td>
</tr>
</tbody>
</table>

Ischemic pain score

Pain free walking time

Ankle Brachial Index
**Toe brachial index**

![Graph of Toe Brachial Index](image)

*A* Represents $P < 0.05$ compared with baseline data.

† Represents $P < 0.05$ compared with data at 1 month after treatment.

‡ Represents $P < 0.05$ compared with data at 3 months after treatment.

**Clinical ischemic score:**

**Rutherford’s category**

![Bar chart of Rutherford's category](image)

**Proportion of category 1-3**

![Line graph of proportion](image)

**What’s your choice?**

![Images of leg wounds](image)

**Take home message**

There is a future for stem cell technology for ischemic vasculopathy.

---

**The Vascular World is coming together in New York**

**This November**

**Veith**

**And you’re invited!**

**Tuesday, November 13 - Saturday, November 17, 2018**